Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs)
$51.14
pos +0.00
+0.00%
Today's Range: 50.73 - 53.00 | TEVA Avg Daily Volume: 3,763,500
Last Update: 10/17/14 - 4:02 PM EDT
Volume: 0
YTD Performance: 27.59%
Open: $0.00
Previous Close: $51.56
52 Week Range: $36.26 - $55.70
Oustanding Shares: 854,000,000
Market Cap: 44,032,240,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 10 10 8
Moderate Buy 0 0 0 0
Hold 10 10 10 9
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 1
Mean Rec. 1.95 2.00 2.00 2.22
Latest Dividend: 0.29
Latest Dividend Yield: 2.33%
Dividend Ex-Date: 08/19/14
Price Earnings Ratio: 33.46
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
33.46 17.00 26.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-4.68% 27.02% 30.16%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.00 0.26 0.08
Net Income -34.40 -0.62 -0.28
EPS -33.60 -0.60 -0.26
Earnings for TEVA:
EBITDA 5.60B
Revenue 20.31B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.21 $1.27 $4.94 $4.88
Number of Analysts 10 9 14 14
High Estimate $1.29 $1.31 $5.08 $5.25
Low Estimate $1.01 $1.23 $4.65 $4.22
Prior Year $1.27 $1.42 $5.01 $4.94
Growth Rate (Year over Year) -4.49% -10.25% -1.35% -1.24%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bullish
Aug 04, 2014 | 7:56 AM EDT
TEVA price target raised from $50 to $54, UBS said. Neutral rating. Estimate also raised due to higher base sales.

Off the Charts Real Money Pro($)

We raised our stops on Teva and added Staples to the long ideas table.
It is preserving its Copaxone franchise, and the executive changes are good news.

Waiting for the Fed Real Money Pro($)

In a flattish market, transports are strong on FedEx's earnings, and small-caps are underperforming.
Conflicting technical patterns suggest one is healthy and the other could be under the weather.

Teva Is a Trade Opportunity Real Money Pro($)

 Stocks with good fundamentals are getting some respect.

It's Time to Duck Real Money Pro($)

A pullback of at least 10%, seems like a distinct possibility.
Bullish
Mar 28, 2014 | 8:15 AM EDT
TEVA was placed on the US Focus List, Citigroup said. $60 price target. Company offers the bst risk/reward of the group.
Bullish
Mar 19, 2014 | 8:25 AM EDT
TEVA was upgraded from Sell to Neutral, Goldman Sachs said. Copaxone slowdown is largely priced in and the underlying business can deli...
Bullish
Mar 14, 2014 | 7:21 AM EDT
TEVA was upgraded to Neutral, JP Morgan said. $49 price target. Company has several potential paths to creating shareholder value. ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.